about
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's diseaseAltered mRNA editing and expression of ionotropic glutamate receptors after kainic acid exposure in cyclooxygenase-2 deficient mice.Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants.Glutamatergic reinnervation through peripheral nerve graft dictates assembly of glutamatergic synapses at rat skeletal muscle.AMPA receptor regulation at the mRNA and protein level in rat primary cortical culturesErbB3 mRNA leukocyte levels as a biomarker for major depressive disorderFXR1P limits long-term memory, long-lasting synaptic potentiation, and de novo GluA2 translation.Chronic glutamate treatment selectively modulates AMPA RNA editing and ADAR expression and activity in primary cortical neurons.Modulation of dendritic AMPA receptor mRNA trafficking by RNA splicing and editing.Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder.Activity regulation of adenosine deaminases acting on RNA (ADARs).Acute Footshock Stress Induces Time-Dependent Modifications of AMPA/NMDA Protein Expression and AMPA Phosphorylation.The Good and the Bad of Glutamate Receptor RNA Editing.Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.Glutamate receptor RNA editing: a molecular analysis of GluR2, GluR5 and GluR6 in human brain tissues and in NT2 cells following in vitro neural differentiation.Genomic organization of the human GRIK2 gene and evidence for multiple splicing variants.Antidepressants activate CaMKII in neuron cell body by Thr286 phosphorylation.Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels.Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs.Absence of the Fragile X Mental Retardation Protein results in defects of RNA editing of neuronal mRNAs in mouse.Kainate receptor RNA editing is markedly altered by acute spinal cord injury.Stress rapidly dysregulates the glutamatergic synapse in the prefrontal cortex of cocaine-withdrawn adolescent rats.Insulin-like growth factor binding protein 2 in bipolar disorder: An expression study in peripheral tissues.miRNA Editing: New Insights into the Fast Control of Gene Expression in Health and Disease.Differential Enzymatic Activity of Rat ADAR2 Splicing Variants Is Due to Altered Capability to Interact with RNA in the Deaminase Domain.A novel homozygous mutation in GAD1 gene described in a schizophrenic patient impairs activity and dimerization of GAD67 enzymeAntidepressant Treatments Change 5-HT2C Receptor mRNA Expression in Rat Prefrontal/Frontal Cortex and HippocampusGenome-wide analysis of consistently RNA edited sites in human blood reveals interactions with mRNA processing genes and suggests correlations with cell types and biological variablesChronic mild stress induces anhedonic behavior and changes in glutamate release, BDNF trafficking and dendrite morphology only in stress vulnerable rats. The rapid restorative action of ketamineChronic phencyclidine administration reduces the expression and editing of specific glutamate receptors in rat prefrontal cortexAlpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidateAuthor Correction: A novel homozygous mutation in GAD1 gene described in a schizophrenic patient impairs activity and dimerization of GAD67 enzymeNicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer
P50
Q28584204-0731DBCA-61FA-4E9F-952C-5CDA8EE4A0CAQ31010610-8E3E93C6-A8E0-44D4-8426-88F62BD26759Q33445342-5C1B478D-9970-4963-B028-63D74F438522Q33841591-B9C6F346-7BDF-4B1C-8C15-A79EEAACD1D7Q34038248-984D0A08-7A06-4AD4-9EBC-E7F253479E29Q34417778-6F1EE70E-61B5-49B5-B9CF-A206C20B668FQ34625623-DC8432D3-F9C4-4ECB-A5D6-349B9D7699EDQ36191315-FF90664A-C98A-42AB-850A-92CB9DC53586Q36668729-08C1E5C2-7588-4473-B738-E98449993A34Q37347446-8E361A6B-76DC-45ED-9ECD-AD3E6463FA50Q37960348-7380E12A-65E3-44D1-8412-165569791A2AQ38540329-744864C4-5D05-4379-98A7-E34D67E2B780Q38987020-CF09EC3B-9165-4ABA-9757-43BCCA898466Q39981493-7AD4E875-E12E-4FA7-ABA0-C3CFCC3693BEQ40626274-03D52834-1C67-4735-965A-E7EEDA061D9EQ43775693-E471455D-624D-4A0A-849E-72B79BDA0B58Q45217305-6FF4581B-AEEA-496D-BD87-B0B335FDF4F2Q45222260-EF9FCCAE-0EE9-4CBC-A923-C2627E17F138Q46929911-EF4CC385-07AF-49B0-A268-58FBCC30A98AQ47686686-90901703-D737-485C-AD30-383E0A519ACFQ47693496-C38C72EB-0C38-4DB6-9059-D374F0F92D0AQ47963983-5EB7F8CB-E22F-4FFC-93DA-05B3EA4EC98BQ47992428-4BF50F40-6EE2-4117-ADC3-6D4BFC186862Q49823926-99D32EF0-0DCE-4A3C-BDFB-D2DB5DCD95A1Q50117504-F4362E7A-611A-4DA5-A0EE-A59A9E2E7F37Q57811369-C62000DF-D003-44EB-9240-CEB02A31DE19Q60050789-AE7FB37F-AEC6-4124-9CB9-2F5F535F1DC2Q60930420-CFB67768-7704-403A-8DE4-4B658E6DDED5Q64285435-376BDC51-9653-47F7-B62D-639D64CE547DQ80812677-5D8E3AFB-0389-42DF-9577-6F10BBFA65AFQ89596043-D6CFE4E0-09A9-46A3-8B95-F682A8A6ACFFQ90171120-7B541349-BD1C-4B6D-8BA5-7C7D63FD4146Q91733469-77CAF300-FD4B-4525-803A-F1B88940479E
P50
description
researcher ORCID ID = 0000-0002-1127-7764
@en
wetenschapper
@nl
name
Alessandro Barbon
@ast
Alessandro Barbon
@en
Alessandro Barbon
@es
Alessandro Barbon
@nl
type
label
Alessandro Barbon
@ast
Alessandro Barbon
@en
Alessandro Barbon
@es
Alessandro Barbon
@nl
prefLabel
Alessandro Barbon
@ast
Alessandro Barbon
@en
Alessandro Barbon
@es
Alessandro Barbon
@nl
P106
P1153
6602866116
P21
P31
P496
0000-0002-1127-7764